NASDAQ:CLSN

Celsion Stock Forecast, Price & News

$0.87

-0.03 (-3.33 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.85

Now: $0.87▼

$0.92

50-Day Range

$0.57

MA: $0.72▼

$0.93

52-Week Range

$0.43

Now: $0.87▼

$6.50

Volume3.06 million shs

Average Volume3.13 million shs

Market Capitalization$32.56 million

P/E RatioN/A

Dividend YieldN/A

Beta2.42

Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

MarketRank^™

Overall MarketRank^™

1.29 out of 5 stars

Medical Sector

619th out of 1,556 stocks

Pharmaceutical Preparations Industry

313th out of 638 stocks

3.0 Analyst's Opinion

Consensus Rating
Celsion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Celsion has a forecasted upside of 359.8% from its current price of $0.87.
Amount of Analyst Coverage
Celsion has received no research coverage in the past 90 days.

2.8 Community Rank

Outperform Votes
Celsion has received 383 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Celsion has received 313 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Celsion has received 55.03% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote “Outperform” if you believe CLSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Celsion does not currently pay a dividend.
Dividend Growth
Celsion does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celsion insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 20.49% of the stock of Celsion is held by insiders.
Percentage Held by Institutions
Only 13.73% of the stock of Celsion is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Celsion are expected to grow in the coming year, from ($0.66) to ($0.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celsion is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celsion is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celsion has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CLSN

Previous Symbol

CUSIPN/A

CIK749647

Webwww.celsion.com

Phone609-896-9100

Employees29

Debt

Debt-to-Equity Ratio0.25

Current Ratio3.67

Quick Ratio3.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00

Price / Sales65.11

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.63 per share

Price / Book1.38

Profitability

EPS (Most Recent Fiscal Year)($0.91)

Net Income$-16,850,000.00

Net Margins-4,315.00%

Return on Equity-104.32%

Return on Assets-47.65%

Miscellaneous

Outstanding Shares37,420,000

Market Cap$32.56 million

Next Earnings Date3/24/2021 (Estimated)

OptionableOptionable

$0.87

-0.03 (-3.33 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

Celsion (NASDAQ:CLSN) Frequently Asked Questions

How has Celsion's stock price been impacted by Coronavirus?

Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLSN stock has decreased by 12.1% and is now trading at $0.87.
View which stocks have been most impacted by COVID-19.

Is Celsion a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Celsion stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLSN, but not buy additional shares or sell existing shares.
View analyst ratings for Celsion or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Celsion?

Wall Street analysts have given Celsion a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Celsion wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Celsion.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) posted its quarterly earnings results on Sunday, November, 15th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.11. The biotechnology company earned $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 4,315.00% and a negative return on equity of 104.32%.
View Celsion's earnings history.

When did Celsion's stock split? How did Celsion's stock split work?

Celsion's stock reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLSN?

2 Wall Street analysts have issued 1 year target prices for Celsion's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 359.8% from the stock's current price.
View analysts' price targets for Celsion or view Wall Street analyst' top-rated stocks.

Who are some of Celsion's key competitors?

Some companies that are related to Celsion include Leap Therapeutics (LPTX), Adamas Pharmaceuticals (ADMS), Orgenesis (ORGS), Galectin Therapeutics (GALT), Synlogic (SYBX), Cyclerion Therapeutics (CYCN), PhaseBio Pharmaceuticals (PHAS), Liminal BioSciences (LMNL), Chembio Diagnostics (CEMI), Anixa Biosciences (ANIX), Oncolytics Biotech (ONCY), Rezolute (RZLTD), Corvus Pharmaceuticals (CRVS), Minerva Neurosciences (NERV) and Actinium Pharmaceuticals (ATNM).
View all of CLSN's competitors.

What other stocks do shareholders of Celsion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL).

Who are Celsion's key executives?

Celsion's management team includes the following people:

Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 69, Pay $786.91k)
Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 63, Pay $455.92k)
Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 60, Pay $409.32k)
Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 61, Pay $505.98k)
Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 62)
Ms. Marianne M. Lambertson, VP of Communications & Investor Relations

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $0.87.

How big of a company is Celsion?

Celsion has a market capitalization of $32.56 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here